Navigation Links
Menopause Drug Tied to Breast Cancer Recurrence
Date:2/17/2009

Dutch study of tibolone, also used for osteoporosis but not available in U.S., was stopped early due to increased risk,,

TUESDAY, Feb. 17 (HealthDay News) -- A large study of tibolone, a drug used to treat menopausal symptoms and to prevent osteoporosis, was halted early after researchers found that the synthetic steroid significantly increased the risk of recurrent breast cancer among survivors of the disease.

Tibolone isn't available in the United States but is approved in 90 countries for easing menopausal symptoms and approved in 55 countries as an osteoporosis treatment. Many breast cancer patients use the drug to counteract the effects of early menopause caused by cancer treatments.

The new findings indicate that the drug should not be prescribed to any woman with known, past, or suspected breast cancer, said Prof. Peter Kenemans, of the VU University Medical Center in Amsterdam, Netherlands, and colleagues.

Tibolone acts like the female hormones estrogen and progesterone in relieving menopausal symptoms. But, unlike estrogen and progesterone, it has been believed that tibolone would reduce the risk of some cancers.

This study included almost 3,100 women who'd had surgery for breast cancer. The women were randomly assigned to receive either 2.5 milligrams of tibolone a day or a placebo. The women's mean age at the start of the study was 52.7 years and the mean time since surgery was 2.7 years.

Among the 1,556 women taking tibolone, 237 (15.2 percent) experienced a cancer recurrence, compared with 165 (10.7 percent) of the 1,542 women taking the placebo. That meant that women taking tibolone had a 40 percent increased risk of recurrent cancer. The researchers also found that 70 percent of the recurrences among the women taking tibolone were distant metastases, which are usually fatal.

This increased risk associated with tibolone was so serious that the study was halted six months early. The findings were released Tuesday by The Lancet Oncology.

The researchers noted that the study had a number of limitations -- breast cancer risk factors weren't assessed and detailed analyses weren't conducted on primary tumors. The study authors also said the profile of future groups of breast cancer patients may differ from that of those in this study. For example, tamoxifen use might not be as widespread or patients might be undergoing adjuvant systemic therapy.

Nevertheless, the study authors concluded, "There are insufficient data to establish the safety of tibolone in women who have had breast cancer and do not require or have finished adjuvant therapy."

This is just the latest study to raise concerns about tibolone. A U.S. study released last summer found that women 60 and older who took tibolone to relieve menopausal symptoms were 2.2 times more likely to suffer a stroke than those taking a placebo. The finding prompted an early halt to that study, which was published in the New England Journal of Medicine.

But that same study also found that women taking tibolone had a reduced risk of breast cancer and colon cancer.

More information

The U.S. National Women's Health Information Center has more about menopause treatment



-- Robert Preidt



SOURCE: The Lancet Oncology, news release, Feb. 17, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Newly Published Menopause Study: Bioidentical and FDA-Approved Divigel(R) (estradiol gel) 0.1 Percent Safe and Effective Treatment for Moderate to Severe Hot Flashes Associated With Menopause
2. Study shows younger women with endometrial cancer can safely keep ovaries, avoid early menopause
3. Omega-3s ease depressive symptoms related to menopause
4. Is rapid transition through menopause linked to earlier onset of heart disease?
5. Reduced breast cancer risk: Physical activity after menopause pays off
6. Male Menopause Treatment Provider, ReNEW MAN, Increases Online Presence
7. Why women should eat less, move more and consider wearing transdermal HRT patches during menopause
8. FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia – Painful Sexual Intercourse : Agency Grants New Indication for Bothersome Vaginal Symptom Associated with Menopause
9. New hormone data can predict menopause within a year
10. Menopause Relief: Award-Winning Physician Announces New Cost Effective Drug-Free Guidelines
11. Changes in sex steroids associated with menopause
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Menopause Drug Tied to Breast Cancer Recurrence
(Date:5/26/2016)... , ... May 26, 2016 , ... MadgeTech will be ... engineered, and manufactured in Warner, New Hampshire at the MadgeTech headquarters. With products sold ... monitoring solutions trusted by government agencies, including NASA. , In 2012, NASA strategically ...
(Date:5/26/2016)... ... 26, 2016 , ... An April Gallup survey found rising health care costs ... Sun Health Senior Living (SHSL) may not share those same worries thanks ... copays for the year, while holding the line on increasing their contributions, including premiums, ...
(Date:5/26/2016)... , ... May 26, 2016 , ... ... healthcare supply chain solutions, today announced the organization has earned its ISO 13485 ... standards and is compliant with all rules and policies associated with ISO quality ...
(Date:5/26/2016)... ... May 26, 2016 , ... North Cypress Medical Center hosted ... Club in Cypress. With the help of community partners, the event organizers raised $45,000 ... hope for wounded service members and their families through health, wellness, and therapeutic support. ...
(Date:5/26/2016)... ... ... The MIAMI Institute for Age Management and Intervention celebrates Global Wellness Day with ... Adonis , Wellness Physician of the MIAMI Institute is certified by the American Academy ... , He also heads up FITTLab, the comprehensive medical testing lab located in The ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... GERMANTOWN, Maryland , May 25, 2016 /PRNewswire/ ... dringenden Bedarf zur Steuerung ... N.V. (NASDAQ: QGEN ; Frankfurt Prime ... Entwicklungsvereinbarung mit Therawis Diagnostics GmbH zur Entwicklung und ... sein. Ein erstes Projekt wird die Entwicklung und ...
(Date:5/25/2016)... , May 25, 2016  Zymo Research Corp. ... their new reference materials that help researchers obtain ... collection to analyses. The rapid growth of the ... researchers to have standard methods to improve the ... Biases inherently exist at every step of the ...
(Date:5/25/2016)... YORK , May 25, 2016 ... Market Size, Share, Development, Growth and Demand Forecast to ... Syringe, Insulin Pump and Others)" published by P&S Market ... at $9,998.3 million in 2015, and it is expected ... Based on type, the insulin pump segment is expected ...
Breaking Medicine Technology: